A Long-Term Study in Schizophrenia

Stopped The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.

Conditions

• Schizophrenia

Interventions

• DRUG: Pomaglumetad methionil

Sponsor

Eli Lilly and Company